Gene: KCNK10

54207
K2p10.1|PPP1R97|TREK-2|TREK2
potassium two pore domain channel subfamily K member 10
protein-coding
14q31.3
Ensembl:ENSG00000100433 MIM:605873 Vega:OTTHUMG00000170743 UniprotKB:P57789
NC_000014.9
SNP Mapped
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
3.246e-1 (AD)  6.638e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs11849247chr14:88242159 (GRCh38.p7)T>Calcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
DIP2B0.72
SVEP10.701
UVRAG0.695
NXPE30.694
KIAA1324L0.679
SESTD10.673
L3MBTL40.661
FLNB0.659
STARD130.658
ENOX20.657

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
PPP1R3G-0.403
WNT7B-0.393
EYA2-0.391
KCNJ16-0.39
RXRG-0.361
PPP1R3C-0.339
RLBP1-0.338
DIAPH3-0.325
PIPOX-0.324
RNF43-0.324

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0067181,12-benzoperylene"1,12-benzoperylene results in increased expression of KCNK10 mRNA"26377693
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"27188386
D020106AcrylamideAcrylamide results in decreased expression of KCNK10 mRNA28959563
D016604Aflatoxin B1Aflatoxin B1 results in increased methylation of KCNK10 gene27153756
D000643Ammonium ChlorideAmmonium Chloride affects the expression of KCNK10 mRNA16483693
D016718Arachidonic AcidArachidonic Acid promotes the reaction [KCNK10 protein results in increased transport of Potassium]16075240
C006780bisphenol Abisphenol A results in decreased expression of KCNK10 mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of KCNK10 gene28505145
C018475butyraldehydebutyraldehyde results in increased expression of KCNK10 mRNA26079696
D020245p-Chloromercuribenzoic Acid"[NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"27188386
D020245p-Chloromercuribenzoic Acidp-Chloromercuribenzoic Acid results in decreased expression of KCNK10 mRNA26272509
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of KCNK10 gene20938992
D016572CyclosporineCyclosporine results in decreased methylation of KCNK10 promoter27989131
D004110DiltiazemDiltiazem inhibits the reaction [KCNK10 protein results in increased transport of Potassium]16075240
C118739entinostatentinostat results in decreased expression of KCNK10 mRNA26272509
C118739entinostat"[NOG protein co-treated with entinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"27188386
D004997Ethinyl EstradiolEthinyl Estradiol results in increased expression of KCNK10 mRNA29097150
D005419FlavonoidsFlavonoids results in decreased expression of KCNK10 mRNA18035473
D005439Flufenamic AcidFlufenamic Acid promotes the reaction [KCNK10 protein results in increased transport of Potassium]16075240
D005473FluoxetineFluoxetine results in decreased activity of KCNK10 protein23022515
D005473FluoxetineFluoxetine results in increased expression of KCNK10 mRNA23022515
D005473FluoxetineKCNK10 mRNA affects the susceptibility to Fluoxetine23022515
D005473Fluoxetine[KCNK2 mRNA co-treated with KCNK10 mRNA] affects the susceptibility to Fluoxetine23022515
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of KCNK10 gene20938992
C039281furanfuran results in decreased expression of KCNK10 mRNA24183702
C004312glycidolglycidol results in decreased expression of KCNK10 mRNA24915197
D006221HalothaneHalothane promotes the reaction [KCNK10 protein results in increased transport of Potassium]16075240
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of KCNK10 mRNA26752646
D008528Mefenamic AcidMefenamic Acid promotes the reaction [KCNK10 protein results in increased transport of Potassium]16075240
C042720mercuric bromidemercuric bromide results in decreased expression of KCNK10 mRNA26272509
C042720mercuric bromide"[NOG protein co-treated with mercuric bromide co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"27188386
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of KCNK10 gene20938992
C004925methylmercuric chloridemethylmercuric chloride results in decreased expression of KCNK10 mRNA28001369
D0156551-Methyl-4-phenylpyridinium1-Methyl-4-phenylpyridinium results in decreased expression of KCNK10 mRNA24810058
C406082monomethylarsonous acid[monomethylarsonous acid affects the acetylation of HIST3H3 protein] which affects the methylation of KCNK10 promoter18448484
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of KCNK10 mRNA"25620056
D037742Nanotubes, Carbon"Nanotubes, Carbon results in decreased expression of KCNK10 mRNA"25620056
D009544Niflumic AcidNiflumic Acid promotes the reaction [KCNK10 protein results in increased transport of Potassium]16075240
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"27188386
C496932panobinostatpanobinostat results in decreased expression of KCNK10 mRNA26272509
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of KCNK10 mRNA26272509
C006253pirinixic acidpirinixic acid results in increased expression of KCNK10 mRNA20813756
D011188PotassiumArachidonic Acid promotes the reaction [KCNK10 protein results in increased transport of Potassium]16075240
D011188PotassiumDiltiazem inhibits the reaction [KCNK10 protein results in increased transport of Potassium]16075240
D011188PotassiumFlufenamic Acid promotes the reaction [KCNK10 protein results in increased transport of Potassium]16075240
D011188PotassiumHalothane promotes the reaction [KCNK10 protein results in increased transport of Potassium]16075240
D011188PotassiumMefenamic Acid promotes the reaction [KCNK10 protein results in increased transport of Potassium]16075240
D011188PotassiumNiflumic Acid promotes the reaction [KCNK10 protein results in increased transport of Potassium]16075240
D011441PropylthiouracilPropylthiouracil results in increased expression of KCNK10 mRNA24780913
C017947sodium arsenite[sodium arsenite affects the acetylation of HIST3H3 protein] which affects the methylation of KCNK10 promoter18448484
C017947sodium arsenitesodium arsenite affects the methylation of KCNK10 gene28589171
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of KCNK10 mRNA26377647
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"27188386
C012589trichostatin Atrichostatin A results in decreased expression of KCNK10 mRNA24935251|2627250
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNK10 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of KCNK10 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of KCNK10 mRNA23179753|2438349
D014635Valproic AcidValproic Acid results in increased expression of KCNK10 mRNA23179753
D001335Vehicle EmissionsVehicle Emissions results in decreased methylation of KCNK10 gene25560391

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005244voltage-gated ion channel activity-IEA-  
GO:0005267potassium channel activity-TAS10880510  
GO:0022841potassium ion leak channel activity-IBA21873635  
GO ID GO Term Qualifier Evidence PubMed
GO:0007165signal transduction-NAS10880510  
GO:0007613memory-IEA-  
GO:0030322stabilization of membrane potential-IBA21873635  
GO:0034765regulation of ion transmembrane transport-IEA-  
GO:0071805potassium ion transmembrane transport-IBA21873635  
GO ID GO Term Qualifier Evidence PubMed
GO:0005886plasma membrane-TAS-  
GO:0005887integral component of plasma membrane-IBA21873635  
KEGG ID KEGG Term
hsa04971Gastric acid secretion
Reactome ID Reactome Term Evidence
R-HSA-112316Neuronal SystemTAS
R-HSA-1296071Potassium ChannelsTAS
R-HSA-1296346Tandem pore domain potassium channelsTAS
R-HSA-1299503TWIK related potassium channel (TREK)TAS
R-HSA-397014Muscle contractionTAS
R-HSA-5576886Phase 4 - resting membrane potentialTAS
R-HSA-5576891Cardiac conductionTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal